Lungscreen Australia has adopted Annalise.ai’s clinical decision-support technology to provide its radiologists with AI tools with the goal of faster, more accurate diagnostics, according to the organization.
The deployment of Annalise Enterprise CXR aims to help Lungscreen Australia improve diagnostic accuracy, streamline radiology workflows, and ensure faster, more precise lung disease detection for patients across the country. Lungscreen Australia said this aligns with the organization's mission to provide equitable, affordable care and improving patient outcomes.
Annalise Enterprise CXR is an AI tool that can detect up to 124 findings on chest x-rays. These include findings suggestive of conditions that could require urgent care, such as lung nodules. Annalise.ai is part of Harrison.ai, with the two companies uniting in 2024.
